Cash and cash equivalents (USD, thousands)

Marketable securities (USD, thousands)

Accounts receivable (USD, thousands)

Due from related parties (USD, thousands)

Inventory, net (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Property and equipment, net (USD, thousands)

Intangible assets, net (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable and accrued expenses (USD, thousands)

Due to related parties (USD, thousands)

Short-term lease liabilities (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term debt, net of current portion (USD, thousands)

Long-term lease liabilities (USD, thousands)

Other liabilities (USD, thousands)

Deferred taxes (USD, thousands)

Total liabilities (USD, thousands)

Class A common stock, $ 0.0001 par value (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive income (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

6afe64f1e91c8e6922664278b5fb55b77a64c1b038eb38f6d7bf78bb641629dc

Diagnostic test revenue (USD, thousands)

Other revenue (USD, thousands)

Total revenue (USD, thousands)

Cost of services (USD, thousands)

Gross profit (USD, thousands)

Research and development (USD, thousands)

Selling and marketing (USD, thousands)

General and administrative (USD, thousands)

Impairment loss (USD, thousands)

Other operating expenses, net (USD, thousands)

Loss from operations (USD, thousands)

Change in fair value of warrants (USD, thousands)

Change in fair value of warrants and contingent liabilities (USD, thousands)

Change in fair value of warrants and earn-out contingent liabilities (USD, thousands)

Interest expense, net (USD, thousands)

Interest (expense) income, net (USD, thousands)

Other income, net (USD, thousands)

Other (expense) income, net (USD, thousands)

Other expense, net (USD, thousands)

Total non-operating expenses, net (USD, thousands)

Total non-operating (expense) income, net (USD, thousands)

Total non-operating income, net (USD, thousands)

Loss before income taxes (USD, thousands)

Income tax (expense) benefit (USD, thousands)

Income tax benefit (USD, thousands)

Net loss (USD, thousands)

Other comprehensive income (loss), net of tax (USD, thousands)

Other comprehensive income, net of tax (USD, thousands)

Other comprehensive loss, net of tax (USD, thousands)

Comprehensive loss (USD, thousands)

Weighted average shares outstanding of Class A common stock (shares)

Basic and diluted loss per share, Class A common stock (USD, per share)

Basic and diluted net loss per share, Class A common stock (USD, per share)

46c548d4d2fb435b075bd75f3b8880a75f4c7ecfaba898e54a7dd46057149be5

6ce117eb6a591f79dbfc296489c44579081b719594acfb41d6e105073b666ebc

Number of exome and genome tests (tests)

Percentage of total test results that are exome and genome (percent)

166505cfb1f5c0c1f50e32fcc15af7618b9c4e3b29ab21267ba70c97e486a265

GeneDx

- Patients with third-party insurance

- Institutional customers

- Self-pay patients

Legacy Sema4

Other Revenue

- Fabric Genomics and Legacy Sema4

Total Revenue

3213224c2655542e47b973df56c294cced03ca9348070c0ca2b4b90783ebeb73

GeneDx Holdings (WGS)

Financials